Business Description
Imugene Ltd
ISIN : AU000000IMU9
Description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 252.07 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -38.7 | |||||
| 3-Year EPS without NRI Growth Rate | -26 | |||||
| 3-Year FCF Growth Rate | -18.6 | |||||
| 3-Year Book Growth Rate | 28.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.07 | |||||
| 9-Day RSI | 32.95 | |||||
| 14-Day RSI | 33.06 | |||||
| 6-1 Month Momentum % | 150 | |||||
| 12-1 Month Momentum % | -19.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.73 | |||||
| Quick Ratio | 5.73 | |||||
| Cash Ratio | 4.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.2 | |||||
| Shareholder Yield % | -8.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.23 | |||||
| ROA % | -41.83 | |||||
| ROIC % | -183.06 | |||||
| ROC (Joel Greenblatt) % | -745.25 | |||||
| ROCE % | -48.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.07 | |||||
| Price-to-Tangible-Book | 3.95 | |||||
| EV-to-EBIT | -4.52 | |||||
| EV-to-Forward-EBIT | -10.28 | |||||
| EV-to-EBITDA | -4.52 | |||||
| EV-to-Forward-EBITDA | -8.39 | |||||
| EV-to-FCF | -6.03 | |||||
| Price-to-Net-Current-Asset-Value | 3.95 | |||||
| Price-to-Net-Cash | 7.9 | |||||
| Earnings Yield (Greenblatt) % | -22.11 | |||||
| FCF Yield % | -13.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imugene Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.013 | ||
| Beta | 3.59 | ||
| Volatility % | 172.52 | ||
| 14-Day RSI | 33.06 | ||
| 14-Day ATR (A$) | 0.006987 | ||
| 20-Day SMA (A$) | 0.0935 | ||
| 12-1 Month Momentum % | -19.23 | ||
| 52-Week Range (A$) | 0.039 - 0.15 | ||
| Shares Outstanding (Mil) | 7,481.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imugene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imugene Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imugene Ltd Frequently Asked Questions
What is Imugene Ltd(ASX:IMU)'s stock price today?
The current price of ASX:IMU is A$0.08. The 52 week high of ASX:IMU is A$0.15 and 52 week low is A$0.04.
When is next earnings date of Imugene Ltd(ASX:IMU)?
The next earnings date of Imugene Ltd(ASX:IMU) is .
Does Imugene Ltd(ASX:IMU) pay dividends? If so, how much?
Imugene Ltd(ASX:IMU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers